• Explore /
  • Poster
  • / A phase 1b study of the anti-PD-1 monoclonal antibody BGB-A317 (A317) in combination with the PARP inhibitor BGB-290 (290) in advanced solid tumors.

A phase 1b study of the anti-PD-1 monoclonal antibody BGB-A317 (A317) in combination with the PARP inhibitor BGB-290 (290) in advanced solid tumors.

Abstract Poster

Authors

null

Michael Friedlander

The Prince of Wales Hospital, Randwick, Australia

Michael Friedlander , Tarek Meniawy , Ben Markman , Linda R. Mileshkin , Paul R. Harnett , Michael Millward , Joanne Lundy , Alison E. Freimund , Christie Norris , Song Mu , John Wu , Virginia E. Paton , Lai Wang , Bo Gao

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics and Translational Research,Immunotherapy

Sub Track

Immune Checkpoint Inhibitors

Clinical Trial Registration Number

NCT02660034

Citation

J Clin Oncol 35, 2017 (suppl; abstr 3013)

DOI

10.1200/JCO.2017.35.15_suppl.3013

Abstract #

3013

Poster Bd #

108

Abstract Disclosures

Similar Posters

First Author: Jayesh Desai

First Author: Jayesh Desai

First Author: Seock-Ah Im

First Author: Jayesh Desai